Allegheny Health Network

Cyrus M. Khan, MD, discusses pirtobrutinib for the treatment of mantle cell lymphoma and findings from the phase 1/2 BRUIN study.

Benny Weskler, MBA, MD, FACS, FACCP, discusses the introduction of immune checkpoint inhibitors in the neoadjuvant setting for patients with non–small cell lung cancer.

In an interview, Nathan Bahary, MD, PhD, explains what factors have contributed to the rise in oncology drug shortages, and emphasizes the importance of proactive measures moving forward, while also suggesting the importance of policy changes and increased communication.

Cyrus M. Khan, MD, discusses the phase 1/2 trial of glofitamab for use as a treatment option for patients with relapsed/refractory large B-cell lymphoma.

John Lister, MD, discusses the current role of stem cell transplant in the treatment of T-cell lymphoma, and some of the latest advances in the space.

Adding immunotherapy to chemotherapy is the new standard-of-care treatment for advanced or recurrent endometrial cancer, according to Eirwen Miller, MD.

Nathan Bahary, MD, PhD, discusses how Allegheny Health Network has been able to combat the recent chemotherapy drug shortages seen nationwide.

In an interview, John Lister, MD, discussed the utility of stem cell transplant in T-cell lymphoma, including ongoing clinical trials and future needs.

For Leukemia Awareness Month, Salman Fazal, MD, and Tibor Kovacsovics, MD, discussed the importance of biomarker testing and targeting in diagnosis, prognosis, and treatment of acute myeloid leukemia.

Prerna Mewawalla, MD, discusses how the treatment landscape for multiple myeloma is growing.

Prerna Mewawalla, MD, discusses how she approaches the choice of therapy for relapsed/refractory multiple myeloma now that many different options are available for patients.

In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.

Amid the ongoing chemotherapy drug shortage in the United States, experts like Nathan Bahary, MD, and Anne LaCasce, MD, MMSc, push for the passing of legislation, yet keep their patients their top priority.

Cyrus M. Khan, MD, discusses the issues with PI3K inhibitor trials in patients with chronic lymphocytic leukemia and the potential role of these drugs.

Currently, cytoreductive surgery remains a pillar of modern treatment for peritoneal carcinomatosis.

Nathan Bahary, MD, PhD, discusses the ongoing challenge of chemotherapy drug shortages in the oncology field.

In an interview with Targeted Oncology, Cyrus M. Khan, MD reviewed the recent FDA approvals is the chronic lymphocytic leukemia space. He also discusses other FDA decisions that have recently altered the landscape for the better.

In an interview with Targeted Oncology, Warren C. Swegal, MD, takes a deep dive into the radioactive iodine-refectory differentiated thyroid cancer treatment armamentarium, and predicts the role of key agents in the near future.

For Sarcoma Awareness Month, Lisa B. Ercolano, MD, and Mark Agulnik, MD, discussed the importance of understanding the genomics of sarcomas and how molecular testing can be useful in this space.

Cyrus M. Khan, discusses the current use of PI3K inhibitors to treat patients with chronic lymphocytic leukemia or small lymphocytic lymphoma and how recent ODAC decisions impacted their use.

Lisa B. Ercolano, MD, discusses the treatment of sarcomas in an era of molecular medicine.

The pan-tumor indication for immunotherapy in patients with mismatch repair deficient/microsatellite instability-high cancers has offered new treatment options and emphasized the importance of biomarker testing.

Warren Swegal, MD, explains how lenvatinib in currently used in the differentiated thyroid cancer landscape.

Yazan Samhouri, MD, discusses the latest advancements in the diffuse large B-cell lymphoma treatment landscape.

Glofitimab is the first and only CD20xCD3 T-cell engaging bispecific antibody approved for the treatment of relapsed/refractory DLBCL.

In an interview with Targeted Oncology, Alexander Helfand, MD discussed the current standard practice for testing patients with renal cell carcinoma and administering immunotherapy or targeted therapy.

In an interview with Targeted Oncology, Alexander Helfand, MD, discussed the treatment of GIST in the second-line setting, as well as later lines, including the available options, guideline recommendations, and ongoing research.

In an interview with Targeted Oncology, Salman Fazal, MD, discussed differences between older matched sibling donors vs younger unrelated donors in stem cell transplants and donor preferences at his institution for patients with cancer.

Cyrus M. Khan, MD, discusses the most recent findings that show the efficacy of zanubrutinib for patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

John Nakayama, MD, discusses what the evolution of endometrial cancer treatment has looked like in recent years.